Skip to main content

Search

Reset all filters
117 Result(s)
Sort by

Clinical-phase2-trials-NASH-and-obesity

Clinical-phase2-trials-NASH-and-obesity

Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
Vaccine bluetongue virus serotype 3 sheep cattle

Vaccine bluetongue virus serotype 3 sheep cattle

BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.
biolabs-heidelberg

biolabs-heidelberg

Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
Focus on Alliance Management

Focus on Alliance Management

Stefan Walke, Global Head of Alliance Management, shares his perspectives on Alliance Management and its contribution to the development of successful long-term partnerships.
Management Systems

Management Systems

Suppliers shall use management systems to support continuous improvement and compliance with the Supplier Code of Conduct.
Respiratory Diseases

Respiratory Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Collaboration-with-OxfordBioTherapeutics

Collaboration-with-OxfordBioTherapeutics

Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Kobe

Kobe

The Kobe Pharma Research Institute takes part in the global research and development activities for human pharmaceuticals.
Immunology

Immunology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
Questions and Answers

Questions and Answers

Answers to common questions from both patients and health care professionals regarding Compassionate Use of experimental medications.